Evaluating influenza vaccines: Progress and perspectives

Future Virology

Volumn 11, Issue 5, 2016, Pages 379-393

  Gianchecchi, Elena ^a   Trombetta, Claudia ^b   Piccirella, Simona ^a   Montomoli, Emanuele ^a,b  

^a VisMederi Srl   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

influenza viruses; new technologies; novel antigens and adjuvants; seasonal and pandemic vaccines; universal influenza vaccine

Indexed keywords

INFLUENZA VACCINE; PANDEMIC VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

DRUG FORMULATION; HUMAN; INFLUENZA VIRUS; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; TECHNOLOGY;

EID: 84966706719     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl-2016-0012     Document Type: Review

References (160)

1. Yoon S-W, Webby RJ, Webster RG. Evolution and ecology of influenza a viruses. Curr. Top. Microbiol. Immunol. 385, 359-375 (2014).
2. Tong S, Li Y, Rivailler P et al. A distinct lineage of influenza A virus from bats. Proc. Natl Acad. Sci. USA 109(11), 4269-4274 (2012).
3. Tong S, Zhu X, Li Y et al. New world bats harbor diverse influenza a viruses. PLoS Pathog. 9(10), e1003657-e1003657 (2013).
4. Kocik J, Kołodziej M, Joniec J, Kwiatek M, Bartoszcze M. Antiviral activity of novel oseltamivir derivatives against some influenza virus strains. Acta Biochim. Pol. 61(3), 509-513 (2014).
5. Murphy BR, Webster RG. Orthomyxoviruses. In: Field's Virology (3rd Edition). Fields BN, Knipe DM, Howley PM (Eds). Lippincott-Raven Publishers, PA, USA, 1397-1445 (1996).
6. Hovden AO, Cox RJ, Haaheim LR. Influenza: The virus and prophylaxis with inactivated influenza vaccine in 'at risk' groups, including COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2(3), 229-240 (2007).
7. Mubareka S, Palese P. Influenza virus: The biology of a changing virus. In: Influenza Vaccines for the Future. Birkhäuser Basel, Basel, Switzerland, 3-26 (2010).
8. Rappuoli R, De Giudice G. Influenza Vaccines for the Future (2nd Edition). Springer, Basel, Switzerland, 3-26 (2011).
9. Reperant LA, Grenfell BT, Osterhaus AD. Quantifying the risk of pandemic influenza virus evolution by mutation and re-assortment. Vaccine 33(49), 6955-6966 (2015).
10. Czako R, Subbarao K. Refining the approach to vaccines against influenza A viruses with pandemic potential. Future Virol. 10(9), 1033-1047 (2015).
11. Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. N. Engl. J. Med. 359, 2579-2585 (2008).
12. Thijs C, Knottnerus A. Influenza vaccination and risk of community-acquired pneumonia. Lancet 372, 2112-2113 (2008).
13. Ohmit SE, Gross J, Victor JC, Monto AS. Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination. Vaccine 27, 1050-1054 (2009).
14. Arvia R, Corcioli F, Pierucci F, Azzi A. Molecular markers of influenza B lineages and clades. Viruses 6(11), 4437-4446 (2014).
15. Cox F, Saeland E, Baart M et al. Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine. Virol. J. 12, 210 (2015).
16. Ito T, Couceiro JN, Kelm S et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J. Virol. 72(9), 7367-7373 (1998).
17. Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: human and veterinaryimplications. J. Mol. Genet. Med. 3(1), 158-166 (2008).
18. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb. Mortal. Wkly Rep. 59, 1057-1062 (2010).
19. Gessner BD, Shindo N, Briand S. Seasonal influenza epidemiology in sub-Saharan Africa: A systematic review. Lancet Infect. Dis. 11, 223-235 (2011).
20. Nair H, Brooks WA, Katz M et al. Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta-analysis. Lancet 378, 1917-1930 (2011).
21. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
22. Radin JM, Katz MA, Tempia S et al. Influenza surveillance in 15 countries in Africa, 2006-2010. J. Infect. Dis. 206(Suppl. 1), S14-S21 (2012).
23. Last JM. A Dictionary of Epidemiology. International Epidemiological Association, New York, NY, USA (2001).
24. Potter CW. A history of influenza. J. Appl. Microbiol. 91, 572-579 (2001).
25. World Health, Organization. Vaccines against influenza. Wkly Epidemiol. Rec. 87, 461-476 (2012).
26. WHO Writing Group. Improving influenza vaccine virus selection. Report of a WHO informal consultation. Influ. Other Respir. Viruses 6(2), 142-152 (2012).
27. Ampofo WK, Baylor N, Cobey S et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir. Viruses 6(2), e141-e145 (2012).
28. Ampofo WK, Azziz-Baumgartner E, Bashir U et al. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014. Vaccine 33(36), 4368-4382 (2015).
29. Robertson JS, Inglis SC. Prospects for controlling future pandemics of influenza. Virus Res. 162(1-2): 39-46 (2011).
30. Jackson LA. Using surveillance to evaluate influenza vaccine effectiveness. J. Infect. Dis. 199(2), 155-158 (2009).
31. Jang YH, Seong BL. Options and obstacles for designing a universal influenza vaccine. Viruses 6(8), 3159-3180 (2014).
32. Treanor JJ. Prospects for broadly protective influenza vaccines. Am. J. Prev. Med. 49(6 Suppl. 4), S355-S363 (2015).
33. Hashem AM. Prospects of HA-based universal influenza vaccine. Biomed. Res. Int. 2015, 414637 (2015).
34. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr. Top. Microbiol. Immunol. 333, 43-82 (2009).
35. al-Mazrou A, Scheifele DW, Soong T, Bjornson G. Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel. Can. Med. Assoc. J. 145(3), 213-218 (1991).
36. van Boxtel RA, Verdijk P, de Boer OJ, van Riet E, Mensinga TT, Luytjes W. Safety and immunogenicity of influenza whole inactivated virus vaccines: A Phase I randomized clinical trial. Hum. Vaccines Immunother. 11(4), 983-990 (2015).
37. Ansaldi F, de Florentiis D, Durando P, Icardi G. Fluzone(R) intradermal vaccine: A promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev. Vaccines 11(1), 17-25 (2012).
38. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: formulation and production strategies. Eur. J. Pharm. Biopharm. 94, 251-263 (2015).
39. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirusexpressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 29(12), 2272-2278 (2011).
40. King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 27(47), 6589-6594 (2009).
41. Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: A review and metaanalysis of the literature. Clin. Drug Investigat. 15(1), 1-12 (1998).
42. Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD. Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis. Vaccine 29(34), 5785-5792 (2011).
43. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist[R]; Fluenz): A review of its use in the prevention of seasonal influenza in children and adults. Drugs 71(12), 1591-1622 (2011).
44. Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136(2), 168-175 (2000).
45. Reperant LA, Kuiken T, Osterhaus AD. Adaptive pathways of zoonotic influenza viruses: from exposure to establishment in humans. Vaccine 30(30), 4419-4434 (2012).
46. Russell CA, Fonville JM, Brown AE et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 336(6088), 1541-1547 (2012).
47. Sorrell EM, Wan H, Araya Y, Song H, Perez DR. Minimal molecular constraints for respiratory droplet transmission of an avian-human H9N2 influenza A virus. Proc. Natl Acad. Sci. USA 106(18), 7565-7570 (2009).
48. Imai K, Nakamura K, Mase M, Tsukamoto K, Imada T, Yamaguchi S. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486(7403), 420-428 (2012).
49. Zhang Y, Zhang Q, Kong H et al. H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. Science 340(6139), 1459-1463 (2013).
50. Kimble JB, Angel M, Wan H, Sutton TC, Finch C, Perez DR. Alternative reassortment events leading to transmissible H9N1 influenza viruses in the ferret model. J. Virol. 88, 66-71 (2014).
51. Herfst S, Schrauwen EJ, Linster M et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336(6088), 1534-1541 (2012).
52. Zhang Q, Shi J, Deng G et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 341(6144), 410-414 (2013).
53. Linster M, van Boheemen S, de Graaf M et al. Identification, characterization, and natural selection of mutations driving airborne transmission of A/H5N1 virus. Cell 157(2), 329-339 (2014).
54. Sutton TC, Finch C, Shao H et al. Airborne transmission of highly pathogenic H7N1 influenza virus in ferrets. J. Virol. 88(12), 6623-6666 (2014).
55. Shen Z, Lou K, Wang W. New small-molecule drug design strategies for fighting resistant influenza A. Acta Pharm. Sin. B 5(5), 419-430 (2015).
56. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? Nature 389(6651), 554 (1997).
57. Gao R, Cao B, Hu Y et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368(20), 1888-1897 (2013).
58. Garten RJ, Davis CT, Russell CA et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325, 197-201 (2009).
59. Broadbent AJ, Subbarao K. Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Curr. Opin. Virol. 1, 254-262 (2011).
60. Li GM, Chiu C, Wrammert J et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl Acad. Sci. USA 109(23), 9047-9052 (2012).
61. Eidem S, Tete SM, Jul-Larsen A et al. Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations. Vaccine 33(33), 4146-4154 (2015).
62. Neumann G. H5N1 influenza virulence, pathogenicity and transmissibility: what do we know? Future Virol. 10(8), 971-980 (2015).
63. Subbarao K, Luke C. H5N1 viruses and vaccines. PLoS Pathog. 3(3), e40 (2007).
64. Mann AJ, Noulin N, Catchpole A et al. Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. PLoS ONE 9(5), e93761 (2014).
65. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 194, 159-167 (2006).
66. Baras B, Stittelaar KJ, Simon JH et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3, e1401 (2008).
67. Middleton D, Rockman S, Pearse M et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J. Virol. 83, 7770-7778 (2009).
68. Mann A, Marriott AC, Balasingam S et al. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine 24, 4290-4296 (2006).
69. EMA. EMEA Guidelines on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. http://www.ema.europa.eu
70. van der Laan JW, Herberts C, Lambkin-Williams R et al. Animal models in influenza vaccine testing. Expert Rev. Vaccines 7, 783-793 (2008).
71. Bodewes R, Kreijtz JH, van Amerongen G et al. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J. Virol. 84, 7943-7952 (2010).
72. Bodewes R, Rimmelzwaan GF, Osterhaus AD. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev. Vaccines 9, 59-72 (2010).
73. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350, 896-903 (2004).
74. Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7, e33536 (2012).
75. Coelingh KL, Luke CJ, Jin H, Talaat KR. Development of live attenuated influenza vaccines against pandemic influenza strains. Expert Rev. Vaccines 13(7), 855-871 (2014).
76. Subbarao K, Matsuoka Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol. 21(7), 350-358 (2013).
77. Rockman S, Brown L. Pre-pandemic and pandemic influenza vaccines. Hum. Vaccin. 6(10), 792-801 (2010).
78. Wareing MD, Tannock GA. Live attenuated vaccines against influenza: an historical review. Vaccine 19, 3320-3323 (2001).
79. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 15, 295-323 (2002).
80. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59(1), 1-15 (2004).
81. Tosh PK, Boyce TG, Poland GA. Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin. Proc. 83(1), 77-84 (2008).
82. Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19(25-26), 3444-3450 (2001).
83. Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines 8(6), 679-688 (2009).
84. Chan CY, Tambyah PA. Preflucel(R): A Vero-cell culture-derived trivalent influenza vaccine. Expert Rev. Vaccines 11(7), 759-773 (2012).
85. Lee MS, Hu AY. A cell-based backup to speed up pandemic influenza vaccine production. Trends Microbiol. 20(3), 103-105 (2012).
86. Plosker GL. A/H5N1 prepandemic influenza vaccine (whole virion, Vero cell-derived, inactivated) (Vepacel®). Drugs 72(11), 1543-1557 (2012).
87. Li IW, Chan KH, To KW et al. Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses. J. Clin. Virol. 46(4), 325-330 (2009).
88. Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 25(6), 1256-1273 (2008).
89. Luykx DM, Casteleijn MG, Jiskoot W, Westdijk J, Jongen PM. Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. Eur. J. Pharm. Sci. 23, 65-75 (2004).
90. Coenen F, Tolboom JT, Frijlink HW. Stability of influenza sub-unit vaccine. Does a couple of days outside the refrigerator matter? Vaccine 24, 525-531 (2006).
91. Amorij JP, Meulenaar J, Hinrichs WL et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25, 6447-6457 (2007).
92. PATH. Summary of vaccine stability data (2012). www.pathorg/publications/detailphp?.i=1696
93. Lambach P, Alvarez AM, Hirve S et al. Considerations of strategies to provide influenza vaccine year round. Vaccine 33(47), 6493-6498 (2015).
94. Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 25(6), 1256-1273 (2008).
95. Rosendahl Huber S, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell responses to viral infections-opportunities for peptide vaccination. Front. Immunol. 5, 171 (2014).
96. Gottlieb T, Ben-Yedidia T. Epitope-based approaches to a universal influenza vaccine. J. Autoimmun. 54, 15-20 (2014).
97. Hsu SC, Chargelegue D, Obeid OE, Steward MW. Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. J. Gen. Virol. 80(Pt 6), 1401-1405 (1999).
98. Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 78(13), 7052-7060 (2004).
99. Azizi A, Diaz-Mitoma F. Viral peptide immunogens: current challenges and opportunities. J. Pept. Sci. 13(12), 776-786 (2007).
100. Pinto LA, Berzofsky JA, Fowke KR et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 13(15), 2003-2012 (1999).
101. Nardin EH, Oliveira GA, Calvo-Calle JM et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182(5), 1486-1496 (2000).
102. Engler OB, Dai WJ, Sette A et al. Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol. Immunol. 38(6), 457-465 (2001).
103. Kashala O, Amador R, Valero MV et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 20(17-18), 2263-2277 (2002).
104. Gahery H, Daniel N, Charmeteau B et al. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retroviruses 22(7), 684-694 (2006).
105. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 38(4), 1033-1042 (2008).
106. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol. 179(8), 5033-5040 (2007).
107. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu. Rev. Immunol. 25, 171-192 (2007).
108. Taneichi M, Tanaka Y, Kakiuchi T, Uchida T. Liposome-coupled peptides induce long-lived memory CD8 T cells without CD4 T cells. PLoS ONE 5(11), e15091 (2010).
109. Wang TT, Tan GS, Hai R et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl Acad. Sci. USA 107(44), 18979-18984 (2010).
110. Ninomiya A, Ogasawara K, Kajino K, Takada A, Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 20(25-26), 3123-3129 (2002).
111. Matsui M, Kohyama S, Suda T et al. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A∗0201 transgenic mice. Biochem. Biophys. Res. Commun. 391(3), 1494-1499 (2010).
112. Taneichi M, Tanaka Y, Kakiuchi T, Uchida T. Liposome-coupled peptides induce long-lived memory CD8 T cells without CD4 T cells. PLoS ONE 5(11), e15091 (2010).
113. Ichihashi T, Yoshida R, Sugimoto C, Takada A, Kajino K. Cross-protective peptide vaccine against influenza A viruses developed in HLA-A∗2402 human immunity model. PLoS ONE 6(9), e24626 (2011).
114. Ichihashi T, Satoh T, Sugimoto C, Kajino K. Emulsified phosphatidylserine, simple and effective peptide carrier for induction of potent epitope-specific T cell responses. PLoS ONE 8(3), e60068 (2013).
115. Francis JN, Bunce CJ, Horlock C et al. A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety. Vaccine 33(2), 396-402 (2014).
116. Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 18(14), 1327-1333 (2000).
117. Atsmon J, Caraco Y, Ziv-Sefer S et al. Priming by a novel universal influenza vaccine (Multimeric-001)-A gateway for improving immune response in the elderly population. Vaccine 32(44), 5816-5823 (2014).
118. Amorij JP, Kersten GF, Saluja V et al. Towards tailored vaccine delivery: needs, challenges and perspectives. J. Control. Release 161(2), 363-376 (2012).
119. Carignan D, Thérien A, Rioux G et al. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine. Vaccine 33(51), 7245-7253 (2015).
120. Deng L, Cho KJ, Fiers W, Saelens X. M2e-based universal influenza A vaccines. Vaccines (Basel) 3(1), 105-136 (2015).
121. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10), 1157-1163 (1999).
122. Kim MC, Lee JS, Kwon YM et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral. Res. 99(3), 328-335 (2013).
123. Shim BS, Choi YK, Yun CH et al. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS ONE 6(11), e27953 (2011).
124. Kim MC, Lee YN, Hwang HS et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity. Vaccine 32(44), 5824-5831 (2014).
125. Rappazzo CG, Watkins HC, Guarino CM et al. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice. Vaccine 34(10), 1252-1258 (2016).
126. Lee YN, Kim MC, Lee YT, Kim YJ, Kang SM. Mechanisms of cross-protection by influenza virus M2-based vaccines. Immune Netw. 15(5), 213-221 (2015).
127. Gurwith M, Lock M, Taylor EM et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: A randomised, double-blind, placebo-controlled, Phase 1 study. Lancet Infect. Dis. 13(3), 238-250 (2013).
128. Antrobus RD, Coughlan L, Berthoud TK et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol. Ther. 22(3), 668-674 (2014).
129. Principi N, Esposito S. Adjuvanted influenza vaccines. Hum Vaccin Immunother. 8(1), 59-66 (2012).
130. Vogel FR. Improving vaccine performance with adjuvants. Clin Infect Dis. 3(Suppl. 3), S266-S270 (2000).
131. Jalilian B, Christiansen SH, Einarsson HB, Pirozyan MR, Petersen E, Vorup-Jensen T. Properties and prospects of adjuvants in influenza vaccination-messy precipitates or blessed opportunities? Mol. Cell Ther. 1, 2 (2013).
132. Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, De Rosa A. Current adjuvants and new perspectives in vaccine formulation. Expert Rev. Vaccines. 10(7), 1053-1061 (2011).
133. WTEC Panel Report on international assessment of research and development in rapid vaccine manufacturing. www.wtec.org
134. WHO guidelines on nonclinical evaluation of vaccines. www.who.int
135. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19(9-10), 1180-1187 (2000).
136. Cox RJ, Pedersen G, Madhun AS et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a Phase I clinical trial. Vaccine 29(45), 8049-8059 (2011).
137. Payne LG, Van Nest G, Barchfeld GL, Siber GR, Gupta RK, Jenkins SA. PCPP as a parenteral adjuvant for diverse antigens. Dev. Biol. Stand. 92, 79-87 (1998).
138. Andrianov AK, Decollibus DP, Marin A, Webb A, Griffin Y, Webby RJ. PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies. J. Pharm. Sci. 100(4), 1436-1443 (2011).
139. Gordon DL, Sajkov D, Woodman RJ et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine 30(36), 5407-5416 (2012).
140. Honda-Okubo Y, Saade F, Petrovsky N. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 30(36), 5373-5381 (2012).
141. Sawaengsak C, Mori Y, Yamanishi K et al. Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes. Int. J. Pharm. 473(1-2), 113-125 (2014).
142. Pérez-Girón JV, Belicha-Villanueva A, Hassan E et al. Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity. J. Immunol. 193(3), 1324-1332 (2014).
143. Cooper CL, Davis HL, Morris ML et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22, 3136-3143 (2004).
144. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259(2), 256-261 (1999).
145. Mbawuike I, Zang Y, Couch RB. Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant. Vaccine 25(17), 3263-3269 (2007).
146. Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, Ioannidis JP. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS ONE 6(9), e24384 (2011).
147. Wang B-Z, Xu R, Quan F-S, Kang S-M, Wang L, Compans RW. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS ONE 5(11), e13972 (2010).
148. Treanor JJ, Taylor DN, Tussey L et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28(52), 8268-8274 (2010).
149. Taylor DN, Treanor JJ, Sheldon EA et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30(39), 5761-5769 (2012).
150. Baz M, Paskel M, Matsuoka Y et al. Replication and immunogenicity of swine, equine, and avian h3 subtype influenza viruses in mice and ferrets. J. Virol. 87, 6901-6910 (2013).
151. Renegar KB, Small PAJ. Passive transfer of local immunity to influenza virus by IgA antibody. J. Immunol. 146, 1972-1978 (1991).
152. Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136, 168-175 (2000).
153. Smith DR, Lapedes AS, de Jong JC et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305(5682), 371-376 (2004).
154. Franco LM, Bucasas KL, Wells JM et al. Integrative genomic analysis of the human immune response to influenza vaccination. Elife 2, e00299 (2013).
155. Fiers W, de Filette M, El Bakkouri K et al. M2e-based universal influenza A vaccine. Vaccine 27, 6280-6283 (2009).
156. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu. Rev. Med. 64, 189-202 (2013).
157. McMichael AJ, Gotch FM, Noble GR, Beare PAS. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309, 13-17 (1983).
158. Forrest BD, Pride MW, Dunning AJ et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin. Vaccine Immunol. 15, 1042-1053 (2008).
159. Wilkinson TM, Li CKF, Chui CSC et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18, 274-280 (2012).
160. Sridhar S, Begom S, Bermingham A et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305-1312 (2013).